The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Open accessAbstract
Huntington's disease (HD) is a progressive neurodegenerative illness for which there is no effective therapy. We examined whether creatine, which may exert neuroprotective effects by increasing phosphocreatine levels or by stabilizing the mitochondrial permeability transition, has beneficial effects in a transgenic mouse model of HD (line 6/2). Dietary creatine supplementation significantly improved survival, slowed the development of brain atrophy, and delayed atrophy of striatal neurons and the formation of huntingtin-positive aggregates in R6/2 mice. Body weight and motor performance on the rotarod test were significantly improved in creatine-supplemented R6/2 mice, whereas the onset of diabetes was markedly delayed. Nuclear magnetic resonance spectroscopy showed that creatine supplementation significantly increased brain creatine concentrations and delayed decreases in N-acetylaspartate concentrations. These results support a role of metabolic dysfunction in a transgenic mouse model of HD and suggest a novel therapeutic strategy to slow the pathological process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We found that creatine significantly improves survival, improves motor performance, slows the development of brain atrophy, increases brain ATP levels, delays atrophy of striatal neurons and the formation of Htt-positive aggregates in the R6/2 and N-171-82Q transgenic mouse models of HD118-120.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Self-citationAggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citationDavies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188
Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011
Spatial Localization in NMR Spectroscopy in Vivo
Bottomley, P. A. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb32915.x · Cited by 1,382
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914
Self-citationBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Self-citationHodgson, J., Agopyan, N., Gutekunst, C., Leavitt, B. R., LePiane, F. G., Singaraja, R. R., Smith, D. J., Bissada, N., McCutcheon, K. M., Nasir, J., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80764-3 · Cited by 851
Self-citationMitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Self-citationInhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
Ona, V. O., Li, M., Vonsattel, J. P., Andrews, L. J., Khan, S. Q., Chung, W. M., Frey, A. S., Menon, A., Li, X., Stieg, P. E., et al. (1999) · Nature · doi:10.1038/20446 · Cited by 640
Sawa, A., Wiegand, G. W., Cooper, J. K., Margolis, R. L., Sharp, A. H., Lawler, J. F., Greenamyre, J. T., Snyder, S. H., & Ross, C. A. (1999) · Nature Medicine · doi:10.1038/13518 · Cited by 557
Widespread expression of Huntington's disease gene (IT15) protein product
Sharp, A. H., Loev, S. J., Schilling, G., Li, S.-H., Li, X.-J., Bao, J., Wagster, M. V., Kotzuk, J. A., Steiner, J. P., Lo, A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90345-3 · Cited by 516
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy‐Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485
Self-citationJenkins, B. G., Koroshetz, W. J., Beal, M. F., & Rosen, B. R. (1993) · Neurology · doi:10.1212/wnl.43.12.2689 · Cited by 479
Self-citationNeuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease
Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R. F., & Beal, M. F. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 431
Self-citationInhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo.
Bates, T. E., Strangward, M., Keelan, J., Davey, G. P., Munro, P., & Clark, J. B. (1996) · PubMed · Cited by 422
Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues
Strong, T. V., Tagle, D. A., Valdes, J. M., Elmer, L. W., Boehm, K., Swaroop, M., Kaatz, K. W., Collins, F. S., & Albin, R. L. (1993) · Nature Genetics · doi:10.1038/ng1193-259 · Cited by 417
Creatine deficiency in the brain: A new, treatable inborn error of metabolism
Stöckler, S., Holzbach, U., Hanefeld, F., Marquardt, I., Helms, G., Requart, M., Hänicke, W., & Frahm, J. (1994) · Pediatric Research · doi:10.1203/00006450-199409000-00023 · Cited by 417
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Self-citationCreatine in humans with special reference to creatine supplementation
Balsom, P. D., Söderlund, K., & Ekblom, B. (1994) · Sports Medicine · doi:10.2165/00007256-199418040-00005 · Cited by 404 · cited 1×
“Creatine administration is well tolerated in man, results in increased PCr levels, and may have benefits in pathological conditions (Balsom et al., 1994; Dawson et al., 1995; Greenhaff, 1997).”
BackgroundReddy, P. H., Williams, M., Charles, V., Garrett, L. J., Pike-Buchanan, L., Whetsell, W. O., Miller, G., & Tagle, D. A. (1998) · Nature Genetics · doi:10.1038/2510 · Cited by 399
Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse
Wheeler, V. C. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.1.115 · Cited by 395
Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity
Matthews, R. T., Ferrante, R. J., Klivènyi, P., Yang, L., Klein, A., Mueller, G., Kaddurah-Daouk, R. F., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 374
Self-citationInhibition of N-acetylaspartate production
Bates, T. E., Strangward, M., Keelan, J., Davey, G. P., Munro, P., & Clark, J. B. (1996) · Neuroreport · doi:10.1097/00001756-199605310-00014 · Cited by 365
Huntington aggregates may not predict neuronal death in Huntington's disease.
Kuemmerle, S., Gutekunst, C., Klein, A., Li, X. J., Li, S. H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · PubMed · Cited by 362
Self-citationApoptosis, Excitotoxicity, and Neuropathology
Leist, M., & Nicotera, P. (1998) · Experimental Cell Research · doi:10.1006/excr.1997.4026 · Cited by 287
Steeghs, K., Benders, A. A. G. M., Oerlemans, F. T. J. J., HAAN, A. D., Heerschap, A., Ruitenbeek, W., Jost, C. R., van Deursen, J., Perryman, B., Pette, D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80186-5 · Cited by 252
A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies
Tarnopolsky, M. A., Roy, B. D., & MacDonald, J. R. (1997) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199712)20:12 · Cited by 246
The role of creatine kinase in inhibition of mitochondrial permeability transition
O’Gorman, E., Beutner, G., Dolder, M., Koretsky, A. P., Brdiczka, D. G., & Wallimann, T. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01045-4 · Cited by 243
1 H NMR spectroscopy studies of Huntington's disease
Jenkins, B. G., Rosas, H. D., Chen, Y. I., Makabe, T., Myers, R. H., MacDonald, M. E., Rosen, B. R., Beal, M. F., & Koroshetz, W. J. (1998) · Neurology · doi:10.1212/wnl.50.5.1357 · Cited by 241
Self-citationStöckler, S., Hanefeld, F., & Frahm, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04116-5 · Cited by 240
Landwehrmeyer, G. B., McNeil, S. M., Dure, L. S., Ge, P., Aizawa, H., Huang, Q. M., Ambrose, C. M., Duyao, M. P., Bird, E. D., Bonilla, E., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370213 · Cited by 222
Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes.
Hurlbert, M. S., Zhou, W., Wasmeier, C., Kaddis, F. G., Hutton, J. C., & Freed, C. R. (1999) · Diabetes · doi:10.2337/diabetes.48.3.649 · Cited by 218
Creatine monohydrate increases strength in patients with neuromuscular disease
Tarnopolsky, M. A., & Martin, J. C. (1999) · Neurology · doi:10.1212/wnl.52.4.854 · Cited by 209
Brouillet, M. (1995) · Medical Entomology and Zoology · Cited by 190
Stachowiak, O., Dolder, M., Wallimann, T., & Richter, C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.16694 · Cited by 189
Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina
Sipilä, I., Rapola, J., Simell, O., & Vannas, A. (1981) · New England Journal of Medicine · doi:10.1056/nejm198104093041503 · Cited by 181 · cited 2×
“Long-term administration to patients with gyrate atrophy of the choroid in the retina prevented visual field constriction and resulted in improvement of muscle biopsy findings ( Sipila et al., 1981 ).”
BackgroundJenkins, B. G., Klivènyi, P., Küstermann, E., Andreassen, O. A., Ferrante, R. J., Rosen, B. R., & Beal, M. F. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742108.x · Cited by 170
Self-citationFunctional Aspects of Creatine Kinase in Brain
Hemmer, W., & Wallimann, T. (1994) · Developmental Neuroscience · doi:10.1159/000111342 · Cited by 166
Ferrante, R. J., Gutekunst, C., Persichetti, F., McNeil, S. M., Kowall, N. W., Gusella, J. F., MacDonald, M. E., Beal, M. F., & Hersch, S. M. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-09-03052.1997 · Cited by 162
Self-citationBrdiczka, D. G., Beutner, G., Rück, A., Dolder, M., & Wallimann, T. (1998) · BioFactors · doi:10.1002/biof.5520080311 · Cited by 138
O’Gorman, E., Beutner, G., Wallimann, T., & Brdiczka, D. G. (1996) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(96)00074-6 · Cited by 135
The nutritional biochemistry of creatine
Greenhaff, P. L. (1997) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(97)00116-2 · Cited by 121
Sauter, A., & Rudin, M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38633-8 · Cited by 110
Phosphocreatine-dependent Glutamate Uptake by Synaptic Vesicles
Xu, C. J., Klunk, W. E., Kanfer, J. N., Xiong, Q. P., Miller, G., & Pettegrew, J. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13435 · Cited by 95
Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease
Bogdanov, M. B., Ferrante, R. J., Kuemmerle, S., Klivènyi, P., & Beal, M. F. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062642.x · Cited by 90
Self-citationCarter, A. J., MULLER, R. E., Pschorn, U., & Stransky, W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64062691.x · Cited by 83
KIAA0369, doublecortin-like kinase, is expressed during brain development
Burgess, H. A., Martı́nez, S., & Reiner, O. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991115)58:4 · Cited by 79
Deshpande, S. B., Fukuda, A., & Nishino, H. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6457 · Cited by 69
Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase
Dawson, T. M., Hung, K. E., Dawson, V. L., Steiner, J. P., & Snyder, S. H. (1995) · Annals of Neurology · doi:10.1002/ana.410370122 · Cited by 69
Octamer-dimer Transitions of Mitochondrial Creatine Kinase in Heart Disease
Soboll, S., Brdiczka, D. G., Jahnke, D., Schmidt, A., Schlattner, U., Wendt, S., Wyss, M., & Wallimann, T. (1999) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0925 · Cited by 55
Dunant, Y., Loctin, F., Marsal, J., Müller, D., Párducz, Á., & Rabasseda, X. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb02930.x · Cited by 39
Perspectives on the mitochondrial permeability transition
Bernardi, P., Basso, E., Colonna, R., Costantini, P., Lisa, F. D., Eriksson, O., Fontaine, E. M., Forte, M. A., Ichas, F., Massari, S., et al. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00069-3 · Cited by 37
Corbett, R. J. T., & Laptook, A. R. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.140 · Cited by 25
■ REVIEW : Excitotoxicity, Free Radicals, Necrosis, and Apoptosis
Lipton, S. A., & Nicotera, P. (1998) · The Neuroscientist · doi:10.1177/107385849800400516 · Cited by 11
- Self-citation
Research works printed but not linked: 1
- Gutekunst, 1996, Mitochondrial calcium homeostasis in Huntington's disease fibroblasts., Soc Neurosci Abstr, 22, 227
Cited by
Sorted by citations
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology
MOFFETT, J., Ross, B., Arun, P., Madhavarao, C. N., & Namboodiri, A. M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.12.003 · Cited by 1,443
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Apoptosis and Caspases in Neurodegenerative Diseases
Friedlander, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022366 · Cited by 873
Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0173-z · Cited by 1,057
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi‐Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 847
Metadata
- Authors
- Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F.
- Affiliations
- Boston University (US)
- Harvard University (US)
- Emory University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2000-06-15
- Volume
- 20
- Issue
- 12
- Pages
- 4389-4397
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6772461
- OpenAlex
- W1750171938
- Cited by
- 522
- References
- 62
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 7 · 2023: 8 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 12 · 2018: 10 · 2017: 9 · 2016: 23 · 2015: 7 · 2014: 23 · 2013: 14 · 2012: 21
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health (5r29ns037102-02, AG13846)
- National Institute on Aging (P30AG013846, P01AG012992)
- National Institute of Neurological Disorders and Stroke (NS37102, NS 35255, NS38180, R01NS035255)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Huntington's disease, creatine supplementation, neuroprotection, R6/2 transgenic mice, phosphocreatine, mitochondrial permeability transition, brain atrophy, striatal neurons, huntingtin aggregates, N-acetylaspartate, diabetes onset, motor performance
- MeSH terms
- Huntingtin Protein, Animals, Aspartic Acid, Atrophy, Brain, Corpus Striatum, Creatine, Crosses, Genetic, Female, Humans, Huntington Disease, Magnetic Resonance Imaging, Male, Mice, Inbred Strains, Motor Activity, Nerve Tissue Proteins, Neurons, Nuclear Proteins, Neuroprotective Agents, Dietary Supplements, Animals, Genetically Modified, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
